Summit Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 24, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 24, 2025
SMMT$17.84+9.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $104,862 | $71,425 |
| Restricted cash | 325 | — |
| Short-term investments | 307,487 | 114,817 |
| Prepaid expenses and other current assets | 10,519 | 2,622 |
| Research and development tax credit receivable | 557 | 848 |
| Total current assets | 423,750 | 189,712 |
| Non-current assets: | ||
| Property and equipment, net | 254 | 204 |
| Operating lease right-of-use assets | 7,144 | 5,859 |
| Goodwill | 1,864 | 1,893 |
| Research and development tax credit receivable | 698 | 959 |
| Other assets | 1,850 | 4,322 |
| Total assets | $435,560 | $202,949 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $4,636 | $2,667 |
| Accrued liabilities | 19,554 | 8,783 |
| Accrued compensation | 11,977 | 5,429 |
| Operating lease liabilities, current portion | 3,765 | 2,809 |
| Other current liabilities | 1,797 | 717 |
| Total current liabilities | 41,729 | 20,405 |
| Non-current liabilities: | ||
| Operating lease liabilities, net of current portion | 3,453 | 3,290 |
| Other non-current liabilities | 1,630 | 1,562 |
| Promissory note payable to a related party | — | 100,000 |
| Total liabilities | 46,812 | 125,257 |
| Commitments and contingencies (Note 19) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at December 31, 2024 and 2023, respectively | — | — |
| Common stock, $0.01 par value: 1,000,000,000 shares authorized; 737,626,004 and 701,660,053 shares issued and outstanding at December 31, 2024 and 2023, respectively | 7,376 | 7,017 |
| Additional paid-in capital | 1,598,230 | 1,066,381 |
| Accumulated other comprehensive loss | (2,285) | (2,448) |
| Accumulated deficit | (1,214,573) | (993,258) |
| Total stockholders' equity | 388,748 | 77,692 |
| Total liabilities and stockholders' equity | $435,560 | $202,949 |
The accompanying notes are an integral part of the consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.